




SUPPLEMENTARY FIGURE. Weekly influenza (A), COVID-19* (B), and RSV (C) vaccination coverage† among adults — National Immunization Survey-Adult COVID Module, United States, September–November 2024 and September–November 2023



Abbreviation: RSV = respiratory syncytial virus.

* 2024–2025 COVID-19 vaccines were first available at the end of August 2024, approximately 3 weeks earlier than the 2023–2024 COVID-19 vaccines were first available, in mid-September 2023.

† Estimates presented for influenza (n = 136,195) and updated COVID-19 (n = 112,040) vaccination are among adults aged ≥18 years. Estimates for RSV vaccination are among adults aged ≥75 years (n = 79,566) and aged 60–74 years who are at increased risk for severe RSV disease (n = 8,667). A respondent was considered to be at increased risk for severe RSV disease based on the criteria defined in <https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm#B1> down: chronic lung diseases, diabetes with insulin use, heart conditions, immunocompromised state, solid organ or blood stem cell transplant (including bone marrow transplant), cancer, liver disease, sickle cell disease or thalassemia, or currently lives in a nursing home.